Brief: Precision Biosciences Receives U.S. FDA Clearance Of Investigational New Drug Application For First-In-Class Pbgene-Dmd For Treatment Of Duchenne Muscular Dystrophy
11/02/2026 12:14
Feb 11 (Reuters) - Precision BioSciences Inc DTIL.O: PRECISION BIOSCIENCES RECEIVES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FIRST-IN-CLASS PBGENE-DMD FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Source text: ID:nBw5hwLfna Further company coverage: DTIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing